Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Announces Successful GMP Manufacturing Audit by the Israeli Ministry of Health
YAVNE, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces the successful completion of a Good Manufacturing Practice (GMP) audit of the Company's facility in Yavne, Israel by the Isra...
View HTML
Toggle Summary MediWound to Host First Quarter 2017 Financial Results Conference Call on May 8, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, May 01, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three months ended March 31, 2017 at 7:00 a.m. Eastern time on ...
View HTML
Toggle Summary MediWound's NexoBrid® and EscharEx® to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care Spring
YAVNE, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that seven presentations highlighting the positive clinical results from using NexoBrid® as an enzymatic debridement f...
View HTML
Toggle Summary MediWound Announces Conference Call and Webcast of "Meet the Experts" Panel Discussion Chaired by SunTrust Robinson Humphrey at the 49th American Burn Association Annual Meeting
YAVNE, Israel, March 17, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that a "Meet the Expert" panel chaired by SunTrust Robinson Humphrey and comprised of leading burn specialists from ...
View HTML
Toggle Summary MediWound's NexoBrid® and EscharEx® to be Highlighted in Presentations at the American Burn Association 49th Annual Meeting
YAVNE, Israel, March 14, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 6 presentations highlighting the positive results achieved by clinicians using NexoBrid® as an effective enzymati...
View HTML
Toggle Summary MediWound to Present at the Oppenheimer 27th Annual Healthcare Conference
YAVNE, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Oppenheimer 27th Annual Healthcare Conference taking place from March 21-22...
View HTML
Toggle Summary Cost Analysis Demonstrating Significant Health Care Savings Utilizing NexoBrid® in Burn Management Published in BioMed Research International
YAVNE, Israel, March 03, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that outcomes from an independent cost analysis review utilizing NexoBrid in severe burn management compared with sta...
View HTML
Toggle Summary MediWound Reports 2016 Fourth Quarter and Full Year Financial Results
YAVNE, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2016. Highlights of the fourth quarter of 2016 and recen...
View HTML
Toggle Summary MediWound to Host 2016 Fourth Quarter and Full Year Financial Results Conference Call on February 21, 2017 at 8:30 a.m. Eastern Time
YAVNE, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announces that the Company will release financial results for the three and twelve months ended December 31, 2016, at 7:00 a.m. ...
View HTML
Toggle Summary Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area
YAVNE, Israel , Feb. 09, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces positive results from a phase 2 study that evaluated the safety, pharmacokinetics (transcutaneous absorption) and efficacy ...
View HTML